The Joint Science and Technology Office (JSTO) Defense Threat Reduction Agency (DTRA) has announced an upcoming funding opportunity for members of the Medical CBRN Defense Consortium (MCDC) to develop technologies that can accelerate the identification and immune profile of novel antigens in emerging infectious diseases (EID). JSTO intends to incorporate the final technology into a current vaccine platform to develop significant and persistent protective immunity.
Project Scope and Objectives
Through this program, JSTO aims to address potential threat bacterial, viral and toxin agents exposed to members of the armed services. Specific EID pathogens include, but are not limited to, viral, bacterial and pathogens, as well as synthetic and naturally derived toxins. The funded technologies will be expected to rapidly assess in silico (nucleic acid sequence) data from novel pathogens with epidemic or pandemic potential and identify antigens or specific epitopes that would successfully elicit substantial and sustained protective immunity. The proposed technologies should provide sufficient data for the immediate inclusion of the antigen in an existing multiplex platform to optimize vaccine formulation and delivery.
Summary
While the final solicitation has not yet been published, DTRA anticipates awarding the selected effort in April 2025. If your company has an applicable technology, EverGlade Consulting can help you get a head start on your federal funding journey.
For additional information about EverGlade Consulting, reach out to: [email protected]
